Autonomix Medical, INC 10-Q quarterly reports

Autonomix Medical, Inc. reported increased net losses and significant cash burn in its latest quarterly filing, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Autonomix Medical, Inc. reported a significant increase in net loss for the quarter ended September 30, 2025, while advancing its clinical programs and securing new financing agreements.

Autonomix Medical, a pre-revenue medical device company, reported increased losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite positive clinical trial progress and patent grants.

Autonomix Medical, a clinical-stage medical device company, announced its Q3 2025 financial results, detailing a recent public offering and a reverse stock split.

Autonomix Medical's Q2 2024 report highlights increased operating expenses, a reverse stock split, and ongoing development of their neural sensing and treatment technology.

Autonomix Medical's Q1 2024 results show a widened net loss of $2.7 million, primarily due to increased general and administrative and research and development expenses, as the company progresses with its technology development.

Autonomix Medical's Q3 2023 report details increased operating expenses, a net loss, and the completion of its initial public offering, while also outlining progress in its medical device development.